Sermorelin
Also searched as: GRF 1-29 · Geref
Sermorelin is the first 29 amino acids of growth hormone releasing hormone, which is the shortest fragment that retains the parent hormone's activity. It was formerly marketed as Geref and used diagnostically to assess pituitary function, then withdrawn from the market for commercial reasons.
What the research has looked at
- Growth hormone secretion in diagnostic testing
- Paediatric growth hormone deficiency, historically
- Comparative potency against full-length GHRH
This is a description of what has been studied, not a claim about what it does. Evidence level: human trials.
Legal position in the UK
Not a licensed medicine in the UKNo current UK marketing authorisation. Prohibited in sport under WADA class S2.
Handling and storage
Lyophilised powder. Short half-life relative to the DAC-modified analogues, which is the practical difference people are usually asking about.
Vial sizes: Commonly 2mg or 5mg per vial. Where a manufacturer supplies handling instructions, those take precedence over anything general.
Questions
- Why was Geref withdrawn?
- Commercial reasons rather than a safety withdrawal. Diagnostic use declined as alternative testing became standard.
- How does sermorelin differ from CJC-1295?
- CJC-1295 is a modified analogue designed to resist breakdown and, in the DAC form, to bind albumin for a far longer half-life. Sermorelin is the unmodified 1-29 fragment and clears quickly.